-
Start Preamble
Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 11, 2012, Agilent Technologies, 25200 Commercentre Drive, Lake Forest, California 92630-8810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:
Drug Schedule Phencyclidine (7471) II Start Printed Page 30026 1-Piperidinocyclohexane- carbonitrile (8603) II Benzoylecgonine (9180) II The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 20, 2012.
Start SignatureDated: May 11, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 2012-12268 Filed 5-18-12; 8:45 am]
BILLING CODE 4410-09-P
Document Information
- Published:
- 05/21/2012
- Department:
- Drug Enforcement Administration
- Entry Type:
- Notice
- Document Number:
- 2012-12268
- Pages:
- 30025-30026 (2 pages)
- PDF File:
- 2012-12268.pdf